A diagnosis of advanced ovarian cancer means learning a lot of new information quickly. One term you’ll hear is “neoadjuvant.” For many stage III or IV patients, treatment starts with chemotherapy rather than surgery. If you understand why this is recommended and know how to support your body from the start, you can manage the weeks and months ahead more easily.
What Is Neoadjuvant Chemotherapy?
The word “neoadjuvant” means “given before the main treatment.” In ovarian cancer, neoadjuvant chemotherapy (NACT) means getting chemotherapy before surgery to remove the tumor. That surgery is called cytoreductive surgery or debulking. The goal is to remove as much tumor as possible, ideally leaving no visible disease.
Not every patient with ovarian cancer gets NACT. Some patients have surgery first. That approach is called primary debulking surgery or PDS. Chemotherapy comes after PDS. Your oncologist will recommend one path based on how much cancer you have, your overall health, and whether complete tumor removal is possible at diagnosis. According to the National Cancer Institute, both approaches work for advanced epithelial ovarian cancer.
NACT Versus Primary Debulking Surgery: What the Evidence Shows
A 2020 meta-analysis in BMC Cancer combined data from multiple randomized trials and found that NACT and PDS produced similar overall survival and progression-free survival in advanced ovarian cancer patients. The meta-analysis also found that perioperative complications (problems around the time of surgery) were lower in the NACT group. This doesn’t mean NACT is better for every patient. It means both paths can work well when doctors choose the right patients.
| Comparison axis | NACT then interval debulking | Primary debulking surgery (PDS) |
|---|---|---|
| Timing of surgery | After 3-4 chemotherapy cycles | Before any chemotherapy |
| Overall survival | Comparable to PDS in multiple randomized trials | Comparable to NACT in multiple randomized trials |
| Perioperative complication rate | Lower, as reported in multiple meta-analyses | Higher due to larger initial operation |
| Typical patient profile | High tumor burden, stage IV, or not fit for major surgery upfront | High likelihood of complete tumor removal at diagnosis |
| Standard drug regimen | Carboplatin plus paclitaxel – 3-4 cycles before, 3 more after surgery | Carboplatin plus paclitaxel – 6 cycles after surgery |
The Standard Drug Regimen
According to both the National Cancer Institute and the American Cancer Society, the most widely used first-line chemotherapy for epithelial ovarian cancer is a combination of carboplatin and paclitaxel. Carboplatin is a platinum-based drug that damages DNA in cancer cells. Paclitaxel is a taxane that prevents cancer cells from dividing. Together, they attack the tumor in two different ways.
Your doctor gives both drugs through a vein or through a port. A port is a small device placed just under the skin in your chest. It makes repeated infusions easier and protects your veins. Your care team will recommend a port if your treatment plan involves multiple cycles over several months. Treatment is organized into cycles of about 21 days. In an NACT course, most patients get three to four cycles before interval debulking surgery. After recovery from surgery, the remaining cycles continue, for a total of six.
What Happens During Each Infusion
Each infusion appointment takes about four to six hours. You receive paclitaxel first, usually over three hours. Carboplatin follows, typically over about one hour. Before the drugs begin, you get pre-medications: usually an antihistamine, a corticosteroid such as dexamethasone, and an anti-nausea medication such as ondansetron or granisetron. These reduce the risk of allergic reactions and nausea during the infusion.
The two to four days after each infusion are often the hardest. Nausea, fatigue, and muscle aches peak during this time. Your oncologist will prescribe anti-nausea medications to take at home. Take them on schedule during this period rather than waiting until nausea becomes severe. Staying ahead of it is generally more manageable than trying to reverse it once it’s fully established.
Hair loss usually begins around week two to three of treatment. Most patients experience significant thinning or full loss with paclitaxel. This is temporary; regrowth typically begins after treatment ends.
Blood Counts and Monitoring Between Cycles
Chemotherapy affects fast-dividing cells, including white blood cells. Your counts will typically drop in the week after infusion, reaching their lowest point (called the nadir) around days 10 to 14. Your team will schedule blood tests around this time. If counts fall too low, your next cycle may be delayed, or you may get an injection of a growth factor medication to support white blood cell production. Never skip these interim blood tests, even if you feel well.
Know the warning signs that require an urgent call to your care team: a fever at or above 38 degrees Celsius (100.4 degrees Fahrenheit), chills, new pain or swelling around your port, difficulty breathing, or sudden worsening of numbness or tingling in your hands or feet. These may signal an infection or a reaction that needs prompt attention.
Managing Peripheral Neuropathy
Numbness, tingling, or burning in your hands and feet (a condition called peripheral neuropathy) is one of the most common side effects of paclitaxel. It can worsen with each cycle and, in some patients, persist after treatment ends. Report any new or worsening neuropathy to your team right away. Your oncologist may adjust your dose or schedule to reduce the risk of permanent nerve injury. For a detailed look at the current evidence on neuropathy support, see the article on peripheral neuropathy from ovarian cancer chemotherapy on this site.
Planning Integrative Support from Day One
Integrative oncology works alongside chemotherapy, not in place of it. The goals are to help your body tolerate treatment, protect quality of life, and support recovery between cycles. Starting this planning before your first infusion (rather than after side effects develop) is likely to be more effective. The most important first step is full disclosure: tell your entire care team (oncologist, pharmacist, and any integrative practitioners) about every supplement, herb, or over-the-counter product you take or plan to take. Some can affect how your body processes carboplatin or paclitaxel.
Nutrition: Maintaining Your Strength
Adequate protein and calorie intake during NACT supports recovery between cycles and helps your immune system maintain function. Nausea, taste changes, and appetite loss can make eating feel like work. Small, frequent meals (five to six per day instead of three large ones) are often easier to manage. Foods served cold or at room temperature tend to cause less nausea than hot meals for many patients during the days after infusion.
Good protein sources that are gentle on a sensitive stomach include eggs, Greek yogurt, cottage cheese, legumes, and soft white fish. If solid food becomes very difficult on the two to three days after infusion, a blended protein drink or a fortified liquid supplement can help. Contact your care team or a registered dietitian if you are losing weight involuntarily, as unintentional weight loss can affect your ability to complete all planned cycles.
Hydration is especially important with carboplatin. Your team may advise drinking two to three liters of water daily in the days around each infusion to help support kidney function. Follow the specific guidance your team provides based on your blood results and body weight.
Curcumin: Reviewing the Preclinical Evidence
Curcumin, the active compound in turmeric root, has attracted research attention in ovarian cancer. A 2024 review of curcumin’s therapeutic potential in ovarian cancer found that curcumin may make cancer cells more sensitive to platinum-based chemotherapy, may help block resistance mechanisms, and has shown anti-proliferative and anti-metastatic activity in laboratory models. The review acknowledged that this evidence remains largely laboratory-based and that well-designed human trials in ovarian cancer patients are still limited. Curcumin is not a standard treatment alongside NACT at this time.
A practical challenge with standard curcumin powder is poor oral absorption (most of it passes through without being well absorbed). The BCM-95 formulation was developed to improve this. A pharmacokinetic study found that BCM-95 curcumin at 500 mg produced significantly higher blood levels than an equivalent dose of standard 95% curcumin extract. If your oncologist approves curcumin supplementation, BCM-95 formulations offer better bioavailability than standard powders. Ask your care team about the appropriate dose and timing relative to your infusion schedule before you begin.
Physical Activity: What the Evidence Supports
Low-to-moderate physical activity during chemotherapy is supported by evidence for managing fatigue and maintaining muscle mass and mood. Gentle walking for 20 to 30 minutes on days when you feel well is a reasonable starting point for most patients. Yoga and light stretching may also be helpful. Avoid high-intensity activity during the two to four days immediately after infusion when fatigue and nausea are at their peak. Your care team can advise on appropriate activity levels based on your current blood counts, fitness baseline, and any surgical recovery considerations.
Questions to Raise Before Your First Cycle
- Why is neoadjuvant chemotherapy being recommended over primary debulking surgery in my specific case?
- How many cycles will I receive before interval debulking surgery, and how many after?
- What anti-nausea medications will I receive at the infusion center, and what will I take at home?
- Is a port recommended, and when should it be placed relative to my first infusion?
- Is an integrative oncology consultation available at this center or by referral?
- Which supplements, if any, should I discontinue before starting chemotherapy?
- What CA-125 level or imaging findings will guide the decision about when to proceed to surgery?
Tracking Your Response: CA-125 and Imaging
Your oncologist will monitor your response to NACT using CA-125 blood tests and CT imaging. CA-125 is a protein often elevated in ovarian cancer. Falling CA-125 levels across cycles are one indicator that the tumor is responding to treatment. CT scans before and after the neoadjuvant phase show how tumor size and spread have changed. These findings together inform the timing and surgical planning for interval debulking.
Looking Further Into Integrative Options
Some patients also ask about repurposed compounds being studied in the integrative oncology space for ovarian cancer. The article on fenbendazole for ovarian cancer: evidence and safety reviews the current evidence base and safety data for one such compound. Any repurposed agent should be disclosed to your oncology team before use, as interactions with active chemotherapy are possible and not fully characterized in all cases.
You can find various integrative oncology products available to review with your care team at your next appointment.
If you are on prescription medication, pregnant, or breastfeeding, speak with a clinician before adding any supplement to your routine.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
